These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 37940446)

  • 1. Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate-Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 Study.
    Yu EY; Berry WR; Gurney H; Retz M; Conter HJ; Laguerre B; Fong PCC; Ferrario C; Todenhöfer T; Gravis G; Piulats JM; Emmenegger U; Shore ND; Romano E; Mourey L; Li XT; Poehlein CH; Schloss C; Appleman LJ; de Bono JS
    Eur Urol Oncol; 2024 Jun; 7(3):509-518. PubMed ID: 37940446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study.
    Yu EY; Kolinsky MP; Berry WR; Retz M; Mourey L; Piulats JM; Appleman LJ; Romano E; Gravis G; Gurney H; Bögemann M; Emmenegger U; Joshua AM; Linch M; Sridhar S; Conter HJ; Laguerre B; Massard C; Li XT; Schloss C; Poehlein CH; de Bono JS
    Eur Urol; 2022 Jul; 82(1):22-30. PubMed ID: 35397952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pembrolizumab plus Abiraterone Acetate and Prednisone in Patients with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Cohort D.
    Yu EY; Ferrario C; Linch MD; Stoeckle M; Laguerre B; Arranz JA; Todenhöfer T; Fong PC; Piulats JM; Berry W; Emmenegger U; Mourey L; Joshua AM; Mar N; Appleman LJ; Conter HJ; Gravis G; Li XT; Schloss C; Poehlein C; de Bono JS
    Eur Urol Oncol; 2024 Jun; ():. PubMed ID: 38926066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study.
    Sternberg CN; Castellano D; de Bono J; Fizazi K; Tombal B; Wülfing C; Kramer G; Eymard JC; Bamias A; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Poole EM; Ozatilgan A; Geffriaud-Ricouard C; de Wit R
    Eur Urol; 2021 Oct; 80(4):497-506. PubMed ID: 34274136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe.
    de Bono JS; Chowdhury S; Feyerabend S; Elliott T; Grande E; Melhem-Bertrandt A; Baron B; Hirmand M; Werbrouck P; Fizazi K
    Eur Urol; 2018 Jul; 74(1):37-45. PubMed ID: 28844372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study.
    Yu EY; Piulats JM; Gravis G; Fong PCC; Todenhöfer T; Laguerre B; Arranz JA; Oudard S; Massard C; Heinzelbecker J; Nordquist LT; Carles J; Kolinsky MP; Augustin M; Gurney H; Tafreshi A; Li XT; Qiu P; Poehlein CH; Schloss C; de Bono JS
    Eur Urol; 2023 Jan; 83(1):15-26. PubMed ID: 36055895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients.
    Efstathiou E; Titus M; Wen S; Troncoso P; Hoang A; Corn P; Prokhorova I; Araujo J; Dmuchowski C; Melhem-Bertrandt A; Patil S; Logothetis CJ
    Eur Urol Oncol; 2020 Feb; 3(1):119-127. PubMed ID: 31412017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
    Smith MR; Saad F; Rathkopf DE; Mulders PFA; de Bono JS; Small EJ; Shore ND; Fizazi K; Kheoh T; Li J; De Porre P; Todd MB; Yu MK; Ryan CJ
    Eur Urol; 2017 Jul; 72(1):10-13. PubMed ID: 28314611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients.
    Azad AA; Eigl BJ; Murray RN; Kollmannsberger C; Chi KN
    Eur Urol; 2015 Jan; 67(1):23-29. PubMed ID: 25018038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Abiraterone Acetate plus Prednisone or Enzalutamide on Patient-reported Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer: Final 12-mo Analysis from the Observational AQUARiUS Study.
    Thiery-Vuillemin A; Poulsen MH; Lagneau E; Ploussard G; Birtle A; Dourthe LM; Beal-Ardisson D; Pintus E; Trepiakas R; Lefresne F; Lukac M; Van Sanden S; Pissart G; Reid A;
    Eur Urol; 2020 Mar; 77(3):380-387. PubMed ID: 31594705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone.
    Graff JN; Beer TM; Alumkal JJ; Slottke RE; Redmond WL; Thomas GV; Thompson RF; Wood MA; Koguchi Y; Chen Y; Latour E; Bergan RC; Drake CG; Moran AE
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32616555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abiraterone acetate after progression with enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: a multi-center retrospective analysis.
    Yamada Y; Matsubara N; Tabata KI; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H; Yano A; Kawakami S
    BMC Res Notes; 2016 Oct; 9(1):471. PubMed ID: 27756383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate.
    Tagawa ST; Ramaswamy K; Huang A; Mardekian J; Schultz NM; Wang L; Sandin R; Lechpammer S; George DJ
    Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):1032-1040. PubMed ID: 33612825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [
    Emmett L; Subramaniam S; Crumbaker M; Nguyen A; Joshua AM; Weickhardt A; Lee ST; Ng S; Francis RJ; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Gedye C; Rutherford NK; Sandhu S; Kumar AR; Pook D; Ramdave S; Nadebaum DP; Voskoboynik M; Redfern AD; Macdonald W; Krieger L; Schembri G; Chua W; Lin P; Horvath L; Bastick P; Butler P; Zhang AY; Yip S; Thomas H; Langford A; Hofman MS; McJannett M; Martin AJ; Stockler MR; Davis ID;
    Lancet Oncol; 2024 May; 25(5):563-571. PubMed ID: 38621400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abiraterone or Enzalutamide for Patients With Metastatic Castration-Resistant Prostate Cancer.
    La J; Wang L; Corrigan JK; Lang D; Lee MH; Do NV; Brophy MT; Paller CJ; Fillmore NR
    JAMA Netw Open; 2024 Aug; 7(8):e2428444. PubMed ID: 39150709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).
    Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; Shore ND; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Van Poppel H; Carles J; Flaig TW; Efstathiou E; Yu EY; Higano CS; Taplin ME; Griffin TW; Todd MB; Yu MK; Park YC; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ; Saad F
    Eur Urol; 2014 Nov; 66(5):815-25. PubMed ID: 24647231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.
    Khalaf DJ; Annala M; Taavitsainen S; Finch DL; Oja C; Vergidis J; Zulfiqar M; Sunderland K; Azad AA; Kollmannsberger CK; Eigl BJ; Noonan K; Wadhwa D; Attwell A; Keith B; Ellard SL; Le L; Gleave ME; Wyatt AW; Chi KN
    Lancet Oncol; 2019 Dec; 20(12):1730-1739. PubMed ID: 31727538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide.
    Petrylak DP; Vaishampayan UN; Patel KR; Higano CS; Albany C; Dawson NA; Mehlhaff BA; Quinn DI; Nordquist LT; Wagner VJ; Siegel J; Trandafir L; Sartor O
    ESMO Open; 2021 Apr; 6(2):100082. PubMed ID: 33744812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study.
    Saad F; Efstathiou E; Attard G; Flaig TW; Franke F; Goodman OB; Oudard S; Steuber T; Suzuki H; Wu D; Yeruva K; De Porre P; Brookman-May S; Li S; Li J; Thomas S; Bevans KB; Mundle SD; McCarthy SA; Rathkopf DE;
    Lancet Oncol; 2021 Nov; 22(11):1541-1559. PubMed ID: 34600602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis.
    Brasso K; Thomsen FB; Schrader AJ; Schmid SC; Lorente D; Retz M; Merseburger AS; von Klot CA; Boegemann M; de Bono J
    Eur Urol; 2015 Aug; 68(2):317-24. PubMed ID: 25108579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.